The Future of HCV Therapy: NS4B as an Antiviral Target.
Ontology highlight
ABSTRACT: Chronic hepatitis C virus (HCV) infection is a major worldwide cause of liver disease, including cirrhosis and hepatocellular carcinoma. It is estimated that more than 170 million individuals are infected with HCV, with three to four million new cases each year. The current standard of care, combination treatment with interferon and ribavirin, eradicates the virus in only about 50% of chronically infected patients. Notably, neither of these drugs directly target HCV. Many new antiviral therapies that specifically target hepatitis C (e.g. NS3 protease or NS5B polymerase inhibitors) are therefore in development, with a significant number having advanced into clinical trials. The nonstructural 4B (NS4B) protein, is among the least characterized of the HCV structural and nonstructural proteins
SUBMITTER: Dvory-Sobol H
PROVIDER: S-EPMC3000685 | biostudies-literature | 2010 Nov
REPOSITORIES: biostudies-literature
ACCESS DATA